Abstract:Background A higher circulating plasma ceramide ratio (C16:0/C24:0) is associated with an increased risk of heart failure, even after accounting for standard risk factors including lipid markers. However, the pathobiological mechanisms that underlie this association are incompletely understood. We tested the hypothesis that plasma ceramide ratio (C16:0/C24:0) is associated with adverse cardiac remodeling in the community. Methods and Results We evaluated 2652 Framingham Offspring Study participants (mean age, 66±9 years; 55% women) who attended their eighth examination cycle and underwent routine echocardiography and liquid chromatography–tandem mass spectrometry–based assays for circulating ceramide concentrations. We used multivariable linear regression models to relate C16:0/C24:0 (independent variable) to the following echocardiographic measures (dependent variables; separate models for each): left ventricular mass, left ventricular ejection fraction, left atrial emptying fraction, left atrial end‐systolic volume, E/e′ (a measure of left ventricular diastolic function), and left ventricular global circumferential and longitudinal strain by speckle‐tracking echocardiography. In multivariable‐adjusted analyses, higher C16:0/C24:0 per standard deviation increment was associated with lower left ventricular ejection fraction (0.991‐fold change in left ventricular ejection fraction; P =0.0004), worse global circumferential strain (β=0.34, P =0.004), higher left atrial end‐systolic volume (β=2.48, p<0.0001), and lower left atrial emptying fraction (0.99‐fold change; P <0.0001). The C16:0/C24:0 ratio was not associated with either E/e′ or global longitudinal strain, and the association with higher left ventricular mass was rendered statistically nonsignificant upon correction for multiple comparisons. Conclusions Our cross‐sectional observations in a large community‐based sample are consistent with a potential detrimental impact of higher ceramide ratio (C16:0/24:0) on cardiac remodeling traits, which may partly explain the associations of these molecular species with clinical heart failure. Clinical Perspective What Is New? We used a high‐throughput liquid chromatography–mass spectrometry assay to quantify ratios of ceramide molecular species in the plasma and subsequently assessed their relations to echocardiographic measures of cardiac remodeling. Data from the Framingham Offspring Study demonstrate that higher plasma ceramide ratio (C16:0/24:0) is associated with potentially detrimental changes in echocardiographic measures of cardiac structure and function. What Are the Clinical Implications? Our study observations support the notion that the association between higher ceramide ratio (C16:0/24:0) and the subsequently increased risk of clinical heart failure may be partly explained by relations with unfavorable subclinical cardiac structural and functional alterations. Introduction Heart failure (HF) remains a leading cause of morbidity and mortality, affecting 6.5 million Americans, and its prevalence is expected to rise with the aging of the US population. 1 Given the substantial and rising burden of HF, ongoing efforts are needed to uncover novel mechanistic pathways that may underlie disease pathogenesis and progression. One area of recent interest is the role of plasma ceramide biomarkers in the pathogenesis of cardiovascular disease (CVD), including HF. Ceramides are bioactive lipids with a sphingoid base and a fatty acyl chain that are present in cell membranes and plasma, and have major influences on cellular signaling, differentiation, senescence, and programmed cell death. 2 Ceramide synthases facilitate variable acetylation of the sphingoid base, producing a spectrum of ceramide molecular species. 2 Expression and biomolecular effects of ceramides can vary on the basis of detectable relative proportions of distinct circulating ceramide species and the CVD risk profile. 3 Recent studies have focused, therefore, on analyzing the ratio of select ceramides, such as the ratio of long‐chain to very‐long‐chain ceramide species. 4 , <a class="tab-link" hre -Abstract Truncated-

Ceramides as Mediators of Oxidative Stress and Inflammation in Cardiometabolic Disease

Ceramides—Emerging Biomarkers of Lipotoxicity in Obesity, Diabetes, Cardiovascular Diseases, and Inflammation

Ceramides and other sphingolipids as drivers of cardiovascular disease

Ceramides are Fuel Gauges on the Drive to Cardiometabolic Disease

Ying and Yang of Ceramide in the Vascular Endothelium

Ceramide microdomains: the major influencers of the sphingolipid media platform

Lipidomic Analysis to Assess the Correlation between Ceramides, Stress Hyperglycemia, and HbA1c in Acute Myocardial Infarction

Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification

Ceramides as the molecular link between impaired lipid metabolism, saturated fatty acid intake and insulin resistance: are all saturated fatty acids to be blamed for ceramide-mediated lipotoxicity?

The impact of EPA and DHA on ceramide lipotoxicity in the metabolic syndrome

Ceramide Remodeling and Risk of Cardiovascular Events and Mortality.

Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis

Necessary Role of Ceramides in the Human Microvascular Endothelium During Health and Disease

Emerging Roles for Sphingolipids in Cardiometabolic Disease: A Rational Therapeutic Target?

Sphingolipid Levels and Signaling via Resveratrol and Antioxidant Actions in Cardiometabolic Risk and Disease

Ceramides and mitochondrial homeostasis

Adipocyte Ceramides-The Nexus of Inflammation and Metabolic Disease

Ceramide and Regulation of Vascular Tone

Plasma ceramides as biomarkers for microvascular disease and clinical outcomes in diabetes and myocardial infarction

Inflammatory markers, oxidative stress, and mitochondrial dynamics: Repercussions on coronary artery disease in diabetes

Association of Circulating Ceramides With Cardiac Structure and Function in the Community: The Framingham Heart Study.